摘要
目的观察培美曲塞单药与联合卡铂治疗老年晚期肺腺癌的疗效及不良反应。方法 56例晚期肺腺癌患者,培美曲塞单药治疗27例,培美曲塞联合卡铂治疗29例,评价疗效及不良反应。结果 56例中无CR病例。单药组PR 2例,SD 14例,中位PFS为3.5个月,中位OS为9.1个月;联合组PR 3例,SD 16例,中位PFS为3.9个月,中位OS为9.8个月。两组比较,DCR、中位PFS、中位OS差异均无统计学意义(P>0.05)。不良反应主要为骨髓抑制、胃肠道反应及皮疹。结论培美曲塞二线治疗晚期肺腺癌疗效确切,患者耐受性较好。
Objective To observe the efficacy and adverse effect of pemetrexed single or plus carboplatin as second-line therapy in the treatment of elderly patients with advanced lung adenocarcinoma. Methods The clinical data of 56 patients with advanced lung ad- were analyzed, 27 patients recived the pemetrexed monotherapy, 29 patients recived the pemetrexed plus carhoplatin, and the efficacy and adverse effects were assessed. Results There were no case with CR in 56 patients. In pemetrexed monotherapy, there was 2 cases of PR, 14 cases of SD, 11 ea^es of PD, the DCR was 59.3% , median PFS was 3.5 months, and median OS was 9. 1 months. ;in combination group, there was 3 ease of PR, 16 ease of SD, 10 case of PD, the DCR was 65.5% , median PFS was 3.9 months, and median OS was 9. 8 months. There were no significant differences in DCR, median PFS and median OS between two groups （P 〉 0.05 ）. The eommon adverse effects were myelosuppression, gastrointestinal reactions and rashes. Conclusion Pemetrexed is effi- cacious and tolerable as a second-line therapy for elderly patients with advanced lung adenocarcinoma.
出处
《临床肺科杂志》
2012年第12期2243-2245,共3页
Journal of Clinical Pulmonary Medicine
关键词
肺腺癌
二线治疗
培美曲塞
卡铂
pemetrexed
earboplatin
second-line therapy
lung adenoearcinoma
